<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03219515</url>
  </required_header>
  <id_info>
    <org_study_id>HB16C0010-GJD</org_study_id>
    <nct_id>NCT03219515</nct_id>
  </id_info>
  <brief_title>Herbal Medication (Gongjin-dan) for Chronic Dizziness</brief_title>
  <acronym>GOODNESS</acronym>
  <official_title>Safety, Effectiveness, and Cost-effectiveness of an Herbal Medicine, Gongjin-dan, in Subjects With Chronic Dizziness: a Prospective, Multicenter, Randomized, Double-blinded, Placebo-controlled, Parallel-group, Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyunghee University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyunghee University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, multicenter, randomized, double-blinded, placebo-controlled,
      parallel-group, clinical trial to explore the effectiveness of an herbal medication,
      Gongjin-dan (GJD) for chronic dizziness (Ménière disease, psychogenic dizziness, or dizziness
      of unknown cause), identified as liver-deficiency pattern/syndrome, and assessed with
      Dizziness Handicap Inventory (DHI) ≥ 24 at baseline. Participants will be randomized and
      allocated to either GJD or placebo group with 1:1 ratio and orally administered GJD or
      placebo pills once a day for 8 weeks. For collecting data for cost-effectiveness analysis,
      the participants will be followed up to 12 months from randomization.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2018</start_date>
  <completion_date type="Anticipated">August 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dizziness Handicap Inventory (DHI), change between baseline and endpoint</measure>
    <time_frame>56 days</time_frame>
    <description>Assessment of the impairment caused by dizziness</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dizziness Handicap Inventory (DHI), change between baseline and day 14, day 28, day 42</measure>
    <time_frame>14 days</time_frame>
    <description>Assessment of the impairment caused by dizziness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Vertigo Score (MVS), changes between baseline and day 28 and day 56</measure>
    <time_frame>28 days</time_frame>
    <description>Assessment of the intensity of dizziness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analogue Scale (VAS), changes between baseline and day 28 and day 56</measure>
    <time_frame>28 days</time_frame>
    <description>Assessment of the intensity of dizziness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of episodes (dizziness), changes between baseline and day 28 and day 56</measure>
    <time_frame>28 days</time_frame>
    <description>The frequency score of dizziness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Berg Balance Scale (BBS), changes between baseline and day 28 and day 56</measure>
    <time_frame>28 days</time_frame>
    <description>Assessment of the balance impairment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue Severity Scale (FSS), changes between baseline and day 28 and day 56</measure>
    <time_frame>28 days</time_frame>
    <description>Assessment of the severity of chronic fatigue</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Perceived Effect (GPE)</measure>
    <time_frame>Day 56</time_frame>
    <description>Assessment of a patient's perception of symptom worsening or improvement, Patient-rated outcome, 1 item, 1-7 scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Korean version of Beck Depression Inventory (K-BDI), changes between baseline and day 28 and day 56</measure>
    <time_frame>28 days</time_frame>
    <description>Assessment of the severity of depression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>State-Trait Anxiety Inventory (STAI), changes between baseline and day 28 and day 56</measure>
    <time_frame>28 days</time_frame>
    <description>Assessment of the severity of anxiety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Qi Blood Yin Yang deficiency questionnaire (QBYY-Q), changes between baseline and day 28 and day 56</measure>
    <time_frame>28 days</time_frame>
    <description>Assessment of the level of deficiency pattern/syndrome in traditional Korean medicine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EuroQol five-dimensions questionnaire five-level (EQ-5D-5L), changes between baseline and each assessment</measure>
    <time_frame>Day 0, Day 28, Day 56, Month 4, Month 8, Month 12</time_frame>
    <description>Assessment of the level of quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EuroQol five dimensions questionnaire visual analogue scale (EQ VAS), change between baseline and each assessment</measure>
    <time_frame>Day 0, Day 28, Day 56, Month 4, Month 8, Month 12</time_frame>
    <description>Assessment of the level of quality of life</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Medical expenses on dizziness</measure>
    <time_frame>Day 14, Day 28, Day 42, Day 56, Month 4, Month 8, Month 12</time_frame>
    <description>medical and non-medical expenses to treat dizziness for estimating the incremental cost-effectiveness ratio</description>
  </other_outcome>
  <other_outcome>
    <measure>New Blinding index (New BI)</measure>
    <time_frame>Day 56</time_frame>
    <description>Blinding assessment</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">78</enrollment>
  <condition>Dizziness Chronic</condition>
  <arm_group>
    <arm_group_label>Gongjin-dan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be orally administered Gongjin-dan pills of 3.75g, 1 pill/day, 8 weeks (56 days).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will be orally administered placebo pills of 3.75g, 1 pill/day, 8 weeks (56 days).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gongjin-Dan</intervention_name>
    <description>Gongjin-dan (Iksu Pharmaceutical Co. Ltd, Gwangju, Republic of Korea) is composed of Cervi Parvum, Angelica Gigas Root, Cornus Fruit, Ginseng, Steamed Rehmannia Root, and Musk.</description>
    <arm_group_label>Gongjin-dan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo drugs (similar in appearance, taste, and odor to the Gongjin-dan) contains excipients, coloring agents, binders, flavoring agents, and preservative, and gilt-paper covering. Placebo pills of Gongjin-dan will be also made by Iksu Pharmaceutical Co. Ltd, Gwangju, Republic of Korea.</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age between 20 and 79 years, of either sex

          2. Dizziness originating from Ménière disease, psychogenic cause, or unknown cause

          3. Recurring symptom of dizziness for more than 1 month

          4. Dizziness Handicap Inventory (DHI) score ≥ 24 at baseline

          5. Liver-deficiency pattern/syndrome identified by Traditional Korean Medicine doctors

          6. Willingness to provide written informed consent

        Exclusion Criteria:

          1. Dizziness attributable to vestibular disorders (e.g., benign paroxysmal positional
             vertigo, peripheral vestibulopathy, labyrinthitis, vestibular neuronitis, and others)

          2. Dizziness attributable to central nervous system (CNS) disorders (e.g., cerebellar
             ataxia, stroke, demyelination, vertebrobasilar insufficiency, seizure, increased
             intracranial pressure, Parkinson's disease, migraines, and others)

          3. Cervicogenic dizziness

          4. Dizziness attributable to cardiovascular disorders (e.g., arrhythmia, heart valvular
             disease, anemia, orthostatic hypotension, coronary artery disease, and others)

          5. Any active or uncontrolled disease that might cause dizziness (e.g., uncontrolled
             diabetes mellitus, hypertension, respiratory or endocrinological disorders, and
             others)

          6. Dizziness attributable to medication side effects

          7. Severe chronic or terminal diseases (malignant cancer, tuberculosis, and others)

          8. Intake of other antivertiginous drugs that cannot be discontinued

          9. Following physiotherapy, manual therapy (e.g., vestibular rehabilitation), and/or
             cognitive behavioral therapy for the treatment of dizziness

         10. Aspartate aminotransferase (AST), alanine aminotransferase (ALT), blood urea nitrogen
             (BUN), or creatinine &gt; 3 × upper limit of normal range at baseline

         11. Women of (suspected) pregnancy or breast-feeding

         12. Allergic reactions to the study medications

         13. Suspicion of alcohol and/or drug abuse

         14. Enrollment in another clinical study presently or within 30 days prior to the initial
             administration of the study medications

         15. Difficulty in reliably communicating with the investigators or likelihood of inability
             to follow instructions

         16. Other reason for ineligibility of participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Euiju Lee, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kyunghee University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Euiju Lee, Ph.D.</last_name>
    <phone>+8229589230</phone>
    <email>sasangin@daum.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Seungwon Shin, M.D.</last_name>
    <phone>+8229589730</phone>
    <email>ssw.kmd@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Semyung University Korean Medicine Hospital</name>
      <address>
        <city>Chungju</city>
        <state>Chungcheongbuk-do</state>
        <zip>27429</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mi-Ran Shin, Ph.D.</last_name>
      <phone>+82 43-841-1734</phone>
      <email>shinmr19@hanmail.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dongguk University Ilsan Oriental Hospital</name>
      <address>
        <city>Goyang</city>
        <state>Gyeonggi-do</state>
        <zip>10326</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Seung-Ug Hong, Ph.D.</last_name>
      <phone>+82-31-961-9085</phone>
      <email>heenthsu@hanmail.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pusan National University Korean Medicine Hospital</name>
      <address>
        <city>Yangsan</city>
        <state>Gyeongsangnam-do</state>
        <zip>50612</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hyung-Sik Seo, Ph.D.</last_name>
      <phone>+82 55-360-5630</phone>
      <email>aran99@naver.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kyung Hee University Korean Medicine Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Special Seoul City</state>
        <zip>02447</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eui-ju Lee, Ph.D.</last_name>
      <phone>+8229589230</phone>
      <email>sasangin@daum.net</email>
    </contact>
    <contact_backup>
      <last_name>Seungwon Shin, M.D.</last_name>
      <phone>+829589730</phone>
      <email>ssw.kmd@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Euiju Lee, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Seungwon Shin, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Kerber KA, Baloh RW. The evaluation of a patient with dizziness. Neurol Clin Pract. 2011 Dec;1(1):24-33.</citation>
    <PMID>23634356</PMID>
  </reference>
  <reference>
    <citation>Kroenke K, Lucas CA, Rosenberg ML, Scherokman B, Herbers JE Jr, Wehrle PA, Boggi JO. Causes of persistent dizziness. A prospective study of 100 patients in ambulatory care. Ann Intern Med. 1992 Dec 1;117(11):898-904.</citation>
    <PMID>1443950</PMID>
  </reference>
  <reference>
    <citation>Sokolova L, Hoerr R, Mishchenko T. Treatment of Vertigo: A Randomized, Double-Blind Trial Comparing Efficacy and Safety of Ginkgo biloba Extract EGb 761 and Betahistine. Int J Otolaryngol. 2014;2014:682439. doi: 10.1155/2014/682439. Epub 2014 Jun 25.</citation>
    <PMID>25057270</PMID>
  </reference>
  <reference>
    <citation>Moon E, Her Y, Lee JB, Park JH, Lee EH, Kim SH, Oh MS, Jang CG, Kim SY. The multi-herbal medicine Gongjin-dan enhances memory and learning tasks via NGF regulation. Neurosci Lett. 2009 Dec 11;466(3):114-9. doi: 10.1016/j.neulet.2009.09.033. Epub 2009 Sep 27.</citation>
    <PMID>19788912</PMID>
  </reference>
  <reference>
    <citation>Lee JS, Hong SS, Kim HG, Lee HW, Kim WY, Lee SK, Son CG. Gongjin-Dan Enhances Hippocampal Memory in a Mouse Model of Scopolamine-Induced Amnesia. PLoS One. 2016 Aug 2;11(8):e0159823. doi: 10.1371/journal.pone.0159823. eCollection 2016.</citation>
    <PMID>27483466</PMID>
  </reference>
  <reference>
    <citation>Hong SS, Lee JY, Lee JS, Lee HW, Kim HG, Lee SK, Park BK, Son CG. The traditional drug Gongjin-Dan ameliorates chronic fatigue in a forced-stress mouse exercise model. J Ethnopharmacol. 2015 Jun 20;168:268-78. doi: 10.1016/j.jep.2015.04.001. Epub 2015 Apr 10.</citation>
    <PMID>25865680</PMID>
  </reference>
  <reference>
    <citation>Sunwoo YY, Park SI, Chung YA, Lee J, Park MS, Jang KS, Maeng LS, Jang DK, Im R, Jung YJ, Park SA, Kang ES, Kim MW, Han YM. A Pilot Study for the Neuroprotective Effect of Gongjin-dan on Transient Middle Cerebral Artery Occlusion-Induced Ischemic Rat Brain. Evid Based Complement Alternat Med. 2012;2012:682720. doi: 10.1155/2012/682720. Epub 2012 Jun 6.</citation>
    <PMID>22719787</PMID>
  </reference>
  <reference>
    <citation>Son MJ, Im HJ, Kim YE, Ku B, Lee JH, Son CG. Evaluation of the anti-fatigue effects of a traditional herbal drug, Gongjin-dan, under insufficient sleep conditions: study protocol for a randomised controlled trial. Trials. 2016 Aug 22;17:418. doi: 10.1186/s13063-016-1542-7.</citation>
    <PMID>27550184</PMID>
  </reference>
  <reference>
    <citation>Xue Z, Liu CZ, Shi GX, Liu Y, Li ZX, Zhang ZH, Wang LP. Efficacy and safety of acupuncture for chronic dizziness: study protocol for a randomized controlled trial. Trials. 2013 Dec 13;14:429. doi: 10.1186/1745-6215-14-429.</citation>
    <PMID>24330810</PMID>
  </reference>
  <reference>
    <citation>Jacobson GP, Newman CW. The development of the Dizziness Handicap Inventory. Arch Otolaryngol Head Neck Surg. 1990 Apr;116(4):424-7.</citation>
    <PMID>2317323</PMID>
  </reference>
  <reference>
    <citation>Toupet M, Ferrary E, Grayeli AB. Visual analog scale to assess vertigo and dizziness after repositioning maneuvers for benign paroxysmal positional vertigo. J Vestib Res. 2011;21(4):235-41. doi: 10.3233/VES-2011-0420.</citation>
    <PMID>21846956</PMID>
  </reference>
  <reference>
    <citation>Berg KO, Wood-Dauphinee SL, Williams JI, Maki B. Measuring balance in the elderly: validation of an instrument. Can J Public Health. 1992 Jul-Aug;83 Suppl 2:S7-11.</citation>
    <PMID>1468055</PMID>
  </reference>
  <reference>
    <citation>Hewlett S, Dures E, Almeida C. Measures of fatigue: Bristol Rheumatoid Arthritis Fatigue Multi-Dimensional Questionnaire (BRAF MDQ), Bristol Rheumatoid Arthritis Fatigue Numerical Rating Scales (BRAF NRS) for severity, effect, and coping, Chalder Fatigue Questionnaire (CFQ), Checklist Individual Strength (CIS20R and CIS8R), Fatigue Severity Scale (FSS), Functional Assessment Chronic Illness Therapy (Fatigue) (FACIT-F), Multi-Dimensional Assessment of Fatigue (MAF), Multi-Dimensional Fatigue Inventory (MFI), Pediatric Quality Of Life (PedsQL) Multi-Dimensional Fatigue Scale, Profile of Fatigue (ProF), Short Form 36 Vitality Subscale (SF-36 VT), and Visual Analog Scales (VAS). Arthritis Care Res (Hoboken). 2011 Nov;63 Suppl 11:S263-86. doi: 10.1002/acr.20579. Review.</citation>
    <PMID>22588750</PMID>
  </reference>
  <reference>
    <citation>Kamper SJ, Ostelo RW, Knol DL, Maher CG, de Vet HC, Hancock MJ. Global Perceived Effect scales provided reliable assessments of health transition in people with musculoskeletal disorders, but ratings are strongly influenced by current status. J Clin Epidemiol. 2010 Jul;63(7):760-766.e1. doi: 10.1016/j.jclinepi.2009.09.009. Epub 2010 Jan 8.</citation>
    <PMID>20056385</PMID>
  </reference>
  <reference>
    <citation>Staab JP, Ruckenstein MJ. Chronic dizziness and anxiety: effect of course of illness on treatment outcome. Arch Otolaryngol Head Neck Surg. 2005 Aug;131(8):675-9.</citation>
    <PMID>16103297</PMID>
  </reference>
  <reference>
    <citation>Kim J, Ku B, Kim KH. Validation of the qi blood yin yang deficiency questionnaire on chronic fatigue. Chin Med. 2016 May 2;11:24. doi: 10.1186/s13020-016-0092-y. eCollection 2016.</citation>
    <PMID>27141228</PMID>
  </reference>
  <reference>
    <citation>Bang H, Ni L, Davis CE. Assessment of blinding in clinical trials. Control Clin Trials. 2004 Apr;25(2):143-56.</citation>
    <PMID>15020033</PMID>
  </reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 10, 2017</study_first_submitted>
  <study_first_submitted_qc>July 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 17, 2017</study_first_posted>
  <last_update_submitted>September 22, 2017</last_update_submitted>
  <last_update_submitted_qc>September 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kyunghee University</investigator_affiliation>
    <investigator_full_name>Lee Eui-ju</investigator_full_name>
    <investigator_title>Professor, Ph.D. KMD.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dizziness</mesh_term>
    <mesh_term>Vertigo</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

